RioDerm-001 is under clinical development by Rion and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RioDerm-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RioDerm-001 overview
RioDerm-001 is under development for the treatment of diabetic foot ulcer (DFU). The therapeutic candidate comprises platelet-derived exosomes containing fibrin. It is formulated in the form of powder, and is being developed based on Purified Exosome Product (PEP) technology. it is administered through topical route.
Rion overview
Rion is a clinical-stage biotechnology company. It focuses on developing exosome therapies. The company’s product pipeline includes therapies for the treatment of acute myocardial infarction, female stress urinary incontinence, musculoskeletal and wound healing. It develops Purified Exosome Product (PEP), an innovative biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. Rion is headquartered in Rochester, Minnesota, the US.
For a complete picture of RioDerm-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.